Cancer-associated carbohydrate antigens for clinical diagnostic markers--its effectiveness and limitations.
暂无分享,去创建一个
P. Song | Wei Tang | N. Kokudo | Y. Inagaki | W. Tang
[1] M. Oka,et al. Expression of mucin 1 possessing a 3′‐sulfated core1 in recurrent and metastatic breast cancer , 2015, International journal of cancer.
[2] Daniel Reitz,et al. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer , 2015, Journal of Clinical Pathology.
[3] D. Grootendorst,et al. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. , 2014, Clinical colorectal cancer.
[4] Y. Suh,et al. The Value of Postoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Levels for the Early Detection of Gastric Cancer Recurrence after Curative Resection , 2014, Journal of gastric cancer.
[5] Y. Murakami,et al. Elevated perioperative serum CA 19‐9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma , 2014, Journal of surgical oncology.
[6] H. Yamaue,et al. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma , 2014, Journal of hepato-biliary-pancreatic sciences.
[7] Jianjun Gao,et al. Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer. , 2014, World journal of gastroenterology.
[8] R. Bristow,et al. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. , 2012, Gynecologic oncology.
[9] I. Endo,et al. A novel scoring system for arterial invasion of pancreatic body and tail cancer based on multidetector row computed tomography and biomarkers. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[10] Jianjun Gao,et al. Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China , 2013, Liver Cancer.
[11] M. Páez de la Cadena,et al. Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer , 2013, BMC Cancer.
[12] J. Ahn,et al. Implications of Different CA 15-3 Levels according to Breast Cancer Subtype at Initial Diagnosis of Recurrent or Metastatic Breast Cancer , 2012, Oncology.
[13] Sudhir Srivastava,et al. Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.
[14] M. Makuuchi,et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[15] J. Taylor‐Papadimitriou,et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. , 2011, Frontiers in bioscience.
[16] M. Bidziński,et al. Clinical Significance of Serum CA-125 and Soluble Tumor Necrosis Factor Receptor Type I in Cervical Adenocarcinoma Patients , 2010, International Journal of Gynecologic Cancer.
[17] Wei Tang,et al. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers. , 2009, Bioscience trends.
[18] Kazuro Furukawa,et al. Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers. , 2007, The Biochemical journal.
[19] M. Makuuchi,et al. Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues. , 2007, Hepato-gastroenterology.
[20] L. D. Cas,et al. Serum levels of different tumour markers in patients with chronic heart failure , 2005, European journal of heart failure.
[21] M. Makuuchi,et al. Histochemical expression of sialoglycoconjugates in carcinoma of the papilla of Vater. , 2005, Hepato-gastroenterology.
[22] J. Kihlberg,et al. Role of the Human ST6GalNAc-I and ST6GalNAc-II in the Synthesis of the Cancer-Associated Sialyl-Tn Antigen , 2004, Cancer Research.
[23] R. Bresalier,et al. Mucins and mucin binding proteins in colorectal cancer , 2004, Cancer and Metastasis Reviews.
[24] T. Ando,et al. Synthesis of Disialyl Lewis a (Lea) Structure in Colon Cancer Cell Lines by a Sialyltransferase, ST6GalNAc VI, Responsible for the Synthesis of α-Series Gangliosides* , 2003, Journal of Biological Chemistry.
[25] M. Makuuchi,et al. Association of histochemical expression of Maackia amurensis leukoagglutinin‐positive glycoconjugates with behaviour of human gastric cancer , 2003, Histopathology.
[26] K. Arisawa,et al. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. , 2002, Anticancer research.
[27] R. Goodlad,et al. Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. , 2001, Glycobiology.
[28] H. Satoh,et al. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] K. Krause,et al. Quantitative lectinhistochemical and immunohistochemical studies on the occurrence of alpha(2,3)‐ and alpha(2,6)‐linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features , 1995, Cancer.
[30] M. Sakamoto,et al. Serum and tissue measurements of CA72-4 in ovarian cancer patients. , 1993, Gynecologic oncology.
[31] M. Inoue,et al. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors , 1992 .
[32] R. Hamazoe,et al. CA72-4 compared with carcinoembryonic antigen as a tumour marker for gastric cancer. , 1992, European journal of cancer.
[33] S. Kawa,et al. Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA50. , 1991, Scandinavian journal of gastroenterology.
[34] S. Kawa,et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. , 1991, British Journal of Cancer.
[35] E. Cooper,et al. An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease. , 1990, British Journal of Cancer.
[36] J. Verweij,et al. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] M. Kitagawa,et al. Usefulness of a new tumor marker, span‐1, for the diagnosis of pancreatic cancer , 1990, Cancer.